Strategic partnerships Target pharmaceutical and healthcare organizations familiar with Medlior’s HEOR, RWE, and HTA capabilities, leveraging recent collaboration with Boehringer Ingelheim to position Medlior as a trusted partner for pharma-driven evidence generation and regulatory submissions.

Smaller firm agility Capitalize on Medlior’s lean, women-owned, independent consultancy model to offer personalized, fast-turnaround studies and flexible engagement models that appeal to mid-size pharma, biotech startups, and government health agencies seeking tailored evidence solutions.

AI-enabled value Highlight the use of artificial intelligence and advanced analytics in RWE and HEOR projects to differentiate from competitors, pitching enhanced insights, forecasted outcomes, and more efficient study design for decision-makers.

Real-world expansion Leverage past initiatives like Real World Radar and ongoing RWE capabilities to offer end-to-end real-world data strategies, including data capture, analytics, and evidence synthesis for market access, payer, and HTA submissions.

Market positioning Emphasize track record with leading pharmaceutical and healthcare organizations, governance via HTA submissions, and Women Entrepreneurship Strategy heritage to appeal to customers valuing diverse, credible partners and regulatory-aligned research.